(Q61690576)

English

Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection

scientific article published on 10 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

molecular medicine

0 references

antibiotic resistance

1 reference

based on heuristic

inferred from title

Leishmania infantum

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Pedro J Alcolea

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

A Alonso

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

A Peris

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J M Marcen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

M A Abengozar

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J A Castillo

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

V Larraga

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

10 September 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

48

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

6695-6703

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Decreased sensitivity to meglumine antimoniate (Glucantime) ofLeishmania infantumisolated from dogs after several courses of drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Drug resistance in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmaniasis: new approaches to disease control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Immunology of canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cutaneous leishmaniasis in naturally infected dogs is associated with a T helper-2-biased immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Tissue cytokine responses in canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Expression cloning of a protective Leishmania antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

DNA vaccines induce partial protection against Leishmania mexicana

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Ensuring safety of DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

A heterologous prime/boost immunisation strategy protects against virulent E. ruminantium Welgevonden needle challenge but not against tick challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Associations among immunological, parasitological and clinical parameters in canine visceral leishmaniasis: Emaciation, spleen parasitism, specific antibodies and leishmanin skin test reaction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

The separation and identification by monoclonal antibodies of dog IgG fractions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Anti-Leishmania humoral and cellular immune responses in naturally infected symptomatic and asymptomatic dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmania: naive human T cells sensitized with promastigote antigen and IL-12 develop into potent Th1 and CD8(+) cytotoxic effectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

The interaction between CD8+ cytotoxic T cells and Leishmania-infected macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.08.091

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61690576&oldid=1754776571"